From 8 patients (patients 1-3, 5-7 and 9-10) samples were collected before and after the galactose trial for semi-quantitative N-glycan mass spectrometry analysis (ESI-QTOF) 12 (link).
Briefly, heparinized plasma was combined with an internal control (sialylglycopeptide) and digested in buffered RapiGest SFTM solution. N-glycans were cleaved with PNGase FTM, reacted with RapiFluor-MS, and isolated on a HILIC column. Mass spectrometric analysis was performed on the Waters’ Synapt G2 Si QTOF as previously described.
Normal values were derived from a previously obtained cohort of 31 healthy controls.
All samples were analyzed at the Children’s Hospital of Philadelphia, Philadelphia, USA.
Briefly, heparinized plasma was combined with an internal control (sialylglycopeptide) and digested in buffered RapiGest SFTM solution. N-glycans were cleaved with PNGase FTM, reacted with RapiFluor-MS, and isolated on a HILIC column. Mass spectrometric analysis was performed on the Waters’ Synapt G2 Si QTOF as previously described.
Normal values were derived from a previously obtained cohort of 31 healthy controls.
All samples were analyzed at the Children’s Hospital of Philadelphia, Philadelphia, USA.
